Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06853158

MULTIsite Feasibility of MUSIc Therapy to Address Quality Of Life in Sickle Cell Disease

This is a multi-site, multi-visit feasibility RCT of music therapy (MT) among adolescent and adult patients (aged 14 and older) with sickle cell disease (SCD).

Subjects will be randomized into one of three groups, either (1) 6 visits of in- person MT (InMT:); (2) 1 visit of in-person MT and 5 visits of virtual MT (HybMT); or (3) 1 visit of in-person health education and 5 visits of virtual health education (HybHE).

Cohorts of 15 participants (10 at site 1 and 5 site 2) will be recruited each quarter for 6 quarters to reach 90 participants. Cohorts will maintain a semi-structured recruitment, consenting, assessment, and intervention schedule.

The primary objective of the study is to examine the feasibility of study. This is defined by 6 metrics: (1) completeness of data collection, (2) participant screening, (3) participant recruitment, (4) participant retention, (5) Individual attendance and (6) Home practice. A final determination of "feasibility" for the study will be met if any 4 of the 6 metrics described above are met.

This study will also include a secondary objective of conducting qualitative interviews to assess feasibility of implementation.

Recruiting

Interested in participating?

Request Info

Key information

Age range

14 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

UH Seidman Cancer Center Adult SCD Clinic or UH Rainbow Babies and Children's Hospital Sickle Cell Anemia Center, Cleveland, Ohio, United States

Loading trial locations.

About this study

The objectives of this study are to (1) conduct a feasibility randomized control trial (RCT), to examine the data collection processes, and intervention (in-person music therapy [InMT], hybrid MT [HybMT], and hybrid health education [HybHE]) implementation overall and across 2 sites (University Hospitals/Case Western Reserve University [site 1] and Prisma Health/University of South Carolina [site 2]); and (2) evaluate the implementation of the InMT, HybMT, and HybHE interventions using both quantitative data (study records, stakeholder surveys) and qualitative data (interviews).

Three wellbeing programs for individuals with SCD will be compared: (1) InMT, (2) HybMT, and (3) HybHE. Each intervention includes 6 sessions. The treatment period for each group will be 6 to 8 weeks. Each weekly session will last up to one hour in all arms of the study. MT sessions in the InMT and HybMT arms will include the topics of SCD education and MT rationale, breathing exercises, relaxation, imagery, music making, and review and creation of a coping plan for future challenges. The HybHE group will use an adapted version of Project Patients Empowered and Educated Providers (PEEP). Covered topics include: science of SCD, identifying barriers in the Emergency Department, tools for navigating the healthcare system, healthcare based communication, and review and planning for future challenges.

Semi-structured qualitative interview topics will focus on participants' perceptions of the interventions, perceived benefits and burdens of the interventions, and other barriers and facilitators to in-person and hybrid delivery.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Be aged >=14 years old
  • Have a diagnosis of SCD present in their electronic health record (EHR);
  • Meet Analgesic, Anesthetic, and Addiction Clinical Trial Translations Innovations Opportunities and Networks-American Pain Society Pain Taxonomy (AAPT) criteria for chronic SCD pain which includes:

3a. A diagnosis of SCD confirmed by laboratory testing (present in EHR per eligibility criteria 2)

3b. Reports of ongoing pain present on most days over the past 6 months either in a single location or in multiple locations (to be obtained at screening)

3c. Displaying at least one of the following signs on clinical exam (to be obtained from providers' clinical notes in the EHR

  • Palpation of the region of reported pain elicits focal pain or tenderness;
  • Movement of the region of reported pain elicits focal pain;
  • Decreased range of motion or weakness in the region of reported pain;
  • Evidence of skin ulcer in the region of reported pain;
  • Evidence of hepatobiliary or splenic imaging abnormalities (e.g., splenic infarct, chronic pancreatitis) consistent with the region of reported pain; or
  • Evidence of imaging abnormalities consistent with bone infarction or avascular necrosis in the region of reported;

3d. There is no other diagnosis that better explains the signs and symptoms (to be obtained from providers following referral and pre-screening)

  • Be able to speak and understand English;
  • Have an email address and access to mobile device with a functioning data plan
  • Reporting that pain interfered with daily activities at least 1-2 days in the past week.

Exclusion criteria

  • Have a significant visual, hearing, or cognitive impairment
  • Have previously participated in the MUSIQOLS single-site pilot study at University Hospitals in 2018
  • Are currently engaging in mind-body therapies under the supervision of a healthcare professional specifically for pain management
  • Have a planned major medical event in the next 14 weeks such as (but not limited to) childbirth, orthopedic surgery, gene therapy, or stem cell transplant (These criteria do not include blood transfusions, exchange transfusions, or other pharmacologic pain treatment).

Qualitative interviews will be conducted with ~24 participants who received the interventions (with equal numbers across the InMT, HybMT and HybHE groups). Participants will be purposively sampled to include equal distribution across sites in proportion to recruitment.

Stakeholder surveys and qualitative interviews will be conducted among ~20 relevant staff stakeholders (~10 per site), including healthcare providers & staff, music therapists and HybHE interventionists.

Treatment and study plan

Music Therapy

Behavioral

Participants in the 2 experimental MT conditions (In person MT (InMT) or hybrid (inperson.virtual (HybMT) will receive 6 MT sessions over 6 weeks. Each MT session will last no longer than one hour. This 6-week treatment period may be extended to up to 8 weeks if a scheduling conflict prevents a participant from receiving the 6 MT sessions over 6 consecutive weeks.

Health education

Other

The content for the HybHE control was adapted from Project PEEP: Patients Empowered and Educated Providers. The Sickle Cell Community Consortium developed Project PEEP with a grant from Global Blood Therapeutics. Project PEEP addresses unmet needs directly identified and prioritized by a collective of patients with SCD, caregivers, and community-based organizations. The objective is to provide the tools and resources to improve communication and increase positive patient-provider interactions to receive quality, timely care. For the proposed study, we will use modules from the curriculum developed for patients living with SCD.

Primary outcomes

  1. Multi Musiqols Overall Feasibility (achieving 4/6 of the secondary outcomes).

    Time frame: through study completion, an average of 1 year

    There are 6 feasibility metrics: (1) Data quality (90%), (2) Screening rate (35%), (3) Recruitment rate (90%), (4) Retention rate (70%), (5) Individual attendance (70%) and (6) Home practice (70%). A final determination of "feasibility" for the study will be met if any 4 of the 6 metrics are met.

Secondary outcomes

  1. Data quality and completeness (90% goal)

    Time frame: through study completion, an average of 1 year

    This variable is described as being the number of data elements that are correctly completed in the Multi Musiqols REDCap project. The feasibility goal is 90%

  2. Successful Screening Rate of Enrolled Individuals (35% goal)

    Time frame: At enrollment

    The screening rate as those who were enrolled (i.e., provide written informed consent) divided by those approached for the study who met eligibility criteria. The feasibility goal is 35%.

  3. Successful Recruitment of Participants into the Study (90% goal)

    Time frame: At Enrollment

    This translates into randomizing 90% participants who provided written informed consent

  4. Successful Retention of Participants (70% goal)

    Time frame: through study completion, an average of 1 year

    This metric is defined as the number of participants retained until the final survey time point (6-week follow-up) divided by the number of randomized participants.

  5. Successful Individual Attendance of Study Sessions (70% goal)

    Time frame: through study completion, an average of 1 year

    We will consider individual attendance to be acceptable if a given participant attends 4 of 6 sessions in 8 weeks. These 4 sessions must include the first session and any 3 out of the 4 sessions between sessions 2-5. Individual session attendance will be deemed complete if the participant attends 2/3 of the session including (1) the introduction (discussing experience with the MT or HybHE exercise over previous week, providing education on rationale for intervention); (2) setting of the agenda; and (3) the main intervention (e.g., co-creating the music for the intervention, customizing the place and imagery to participants' preferences, experiencing and recording the intervention).

  6. Successful Individual Home Practice (70%)

    Time frame: At 6 week follow-up

    If a given participant practices intervention exercises at least once per week, this will be coded as engaging in the minimum dose of home practice.

Other outcomes

  1. Participant Satisfaction Question 1

    Time frame: At 6 week follow-up

    Enrolled participants will be asked "How satisfied are you with how your pain was managed during your participation in the study" on the 5-point Likert scale (1-strongly dissatisfied-5-very satisfied). Qu 1 will be asked at treatment completion and at 6-week follow up.

  2. Participant Satisfaction Question 2

    Time frame: At 6 week follow-up

    Enrolled participants will be asked ""Overall how satisfied are you with your treatment during your study participation?" on the same 5-point Likert Scale. Qu 2 will be asked at treatment completion and at 6-week follow up.

  3. Provider Satisfaction Question 1

    Time frame: through study completion, an average of 1 year

    Providers will be asked: "To what degree do you view the InMT, HybMT or HybHE intervention as useful or suitable for this population?" (1- very inappropriate-5-very appropriate).

Study contacts

Contact information is provided by the study sponsor or research team.

Coretta Jenerette, PhD, RN

CONTACT

[email protected]

415-502-4242

Jeffery A Dusek, PhD

CONTACT

[email protected]

949-824-8841

Sponsors and collaborators

Lead sponsor

University of California, Irvine

Other

Collaborators

  • Case Western Reserve University
  • National Center for Complementary and Integrative Health (NCCIH)
  • Prisma Health-Upstate
  • University of California, San Francisco
  • University of Massachusetts, Worcester

Registry information

Official study title

MULTIsite Feasibility of MUSIc Therapy to Address Quality Of Life in Sickle Cell Disease (MULTI-MUSIQOLS)

Acronym: MULTI-MUSIQOLS

Important dates

Study start
2025
Primary completion
2026
Study completion
2027
First posted
Feb 28, 2025
Registry last updated
Jan 29, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.